Boston Scientific stock heads into the open after a 4.8% rebound
Published on 09/16/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock closed at 45.05 USD on the NYSE on September 14, 2026, gaining 4.82% from the prior close of 42.98 USD. The shares traded between a day low of 43.85 USD and a day high of 45.15 USD, with 20,378,245 shares changing hands, per NYSE data reported by Yahoo Finance.
September 14, 2026 in numbers
Boston Scientific Corporation (ISIN US10117L1017, NYSE: BSX) saw a notable rebound on September 14, 2026, as the stock climbed to a 45.05 USD close on the NYSE, compared with a previous close of 42.98 USD, marking a 4.82% daily gain. According to quote data on Yahoo Finance, the day’s trading range spanned from 43.85 USD to 45.15 USD, with volume at 20,378,245 shares and a 52-week range between 42.20 USD and 105.65 USD. The performance still left the shares near the lower end of their 52-week range, underscoring the extent of the recent drawdown versus earlier levels. Trailing performance figures on the same overview showed the year-to-date total return at negative 52.75% as of September 14, 2026, compared with an 11.31% gain for the S&P 500 index, highlighting the stock’s substantial underperformance against the broader market over that period.
As Simply Wall St reported on September 15, 2026, the recent weakness in Boston Scientific’s share price has been linked to an August cyberattack that disrupted manufacturing and shipping, as well as voluntary worldwide recalls of its LUX-Dx insertable cardiac monitors over delayed atrial fibrillation burden alert notifications. The same analysis noted that the stock, despite a 4.82% gain over the most recent day, remained down 13.08% over the past 30 days and roughly 52% year to date, with a last close of 45.05 USD set against an estimated fair value of about 62.69 USD, suggesting that the selloff may have overshot underlying fundamentals.
Outlook for today, September 16, 2026
The quote overview on Yahoo Finance lists the next earnings date for Boston Scientific as October 28, 2026, so quarterly results are not due today and the near-term focus into today’s session remains on how investors reassess the fallout from the cyberattack and device recalls and whether sentiment stabilizes after the recent rebound. Analyst commentary collected in the same overview indicates that the average analyst price target of 62.41 USD continues to sit well above the latest close, with recent rating actions such as BTIG’s September 9, 2026 adjustment of its target still framed within a Buy recommendation, according to the analyst section on Yahoo Finance. Broader market conditions, including the performance of major US indices and healthcare peers, may also shape trading in Boston Scientific today, as investors weigh the stock’s steep year-to-date decline against its longer-term medical device positioning and the market’s risk appetite ahead of upcoming macroeconomic data and sector news.
